Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Article in English | MEDLINE | ID: mdl-38830798

ABSTRACT

The process of apoptotic cell clearance by phagocytes, known as efferocytosis, plays an essential role in maintaining homeostasis. Defects in efferocytosis can lead to inflammatory diseases such as atherosclerosis and autoimmune disorders. Therefore, the maintenance and promotion of efferocytosis are considered crucial for preventing these diseases. In this study, we observed that resveratrol, a representative functional food ingredient, and its glycoside, piceid, promoted efferocytosis in both human THP-1 macrophages differentiated with phorbol 12-myristate 13-acetate and peritoneal macrophages from thioglycolate-elicited mice. Resveratrol and piceid significantly increased mRNA expression and protein secretion of MFG-E8 in THP-1 macrophages. Furthermore, the activation of efferocytosis and the increment in MFG-E8 protein secretion caused by resveratrol or piceid treatment were canceled by MFG-E8 knockdown in THP-1 macrophages. In conclusion, we have demonstrated for the first time that resveratrol and piceid promote efferocytosis through the upregulation of MFG-E8 excretion in human THP-1 macrophages.

2.
Cancer Med ; 13(11): e7196, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38872405

ABSTRACT

OBJECTIVE: To achieve patient-centricity in metastatic renal cell carcinoma (mRCC) treatment, it is essential to clarify the differences in perspectives between patients and physicians. This cross-sectional analysis of a web survey aimed to clarify the differences in expectations and concerns between mRCC patients and physicians regarding systemic mRCC therapy in Japan. METHODS: Surveys from 83 patients and 165 physicians were analyzed. RESULTS: The top three most significant differences in expectations of systemic therapy between patients and physicians (patient-based physician value) were "Chance of achieving treatment-free status" (-30.1%, p < 0.001), "Longer survival" (+25.8%, p < 0.001), and "Chance of eliminating all evidence of disease" (-25.6%, p < 0.001). The top three most significant differences in concerns for systemic therapy between patients and physicians (patient-based physician value) were "Lack of efficacy" (+36.1%, p < 0.001), "Lack of knowledge of treatment" (-28.2%, p < 0.001), and "Daily activities affected by side effects" (+22.3%, p < 0.001). Diarrhea, fatigue/malaise, and nausea/vomiting were patients' most distressing adverse events; 50.6% of patients had difficulty telling their physicians about adverse events such as fatigue, anxiety, and depression. CONCLUSIONS: This study demonstrated a gap between patients with mRCC and physicians in their expectations and concerns for systemic therapy. Japanese patients with mRCC suffer from a number of adverse events, some of which are not shared with physicians. This study highlights the importance of communicating well with patients in clinical practice to achieve patient-centricity in systemic treatment for mRCC.


Subject(s)
Carcinoma, Renal Cell , Kidney Neoplasms , Humans , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/psychology , Carcinoma, Renal Cell/therapy , Cross-Sectional Studies , Male , Female , Japan , Middle Aged , Kidney Neoplasms/drug therapy , Kidney Neoplasms/pathology , Kidney Neoplasms/psychology , Kidney Neoplasms/therapy , Aged , Adult , Physicians/psychology , Surveys and Questionnaires , Physician-Patient Relations , Neoplasm Metastasis , Aged, 80 and over
3.
Cancers (Basel) ; 16(10)2024 May 16.
Article in English | MEDLINE | ID: mdl-38791981

ABSTRACT

Information on the financial toxicity experienced by Japanese patients with metastatic renal cell carcinoma (mRCC) is lacking, even though Japan has its own unique public health insurance system. Thus, a web-based survey was conducted to evaluate the financial toxicity experienced by Japanese mRCC patients using the COmprehensive Score for financial Toxicity (COST) tool. This study enrolled Japanese patients who underwent, or were undergoing, systemic therapy for mRCC. The outcomes evaluated were the distribution of COST scores, the correlation between COST and quality of life (QOL) assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) scale, and demographic factors associated with financial toxicity. The median (range) COST score was 19.0 (3.0-36.0). The Pearson correlation coefficient for COST and FACT-G total scores was 0.40. Univariate analysis revealed that not having private health insurance and lower household income per year were significantly associated with lower COST scores. Multivariate analyses showed that age < 65 years and not having private health insurance were significantly associated with lower COST scores. This study revealed that Japanese mRCC patients experience adverse financial impacts even under the universal health insurance coverage system available in Japan, and financial toxicity negatively affects their QOL.

4.
Contemp Clin Trials Commun ; 30: 101035, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36387994

ABSTRACT

Background: The aim of the trial is to evaluate the effectiveness of interventions provided by online support program apps, adopting health-related quality of life (HR-QOL) scores as indicators. Methods: The design is as an open, randomized, parallel-group trial with longitudinal data collection. The subjects will be female cancer patients receiving treatment in a Japanese National Cancer Hospital. Patients assigned to the experimental group will use three apps: an app for them to monitor their own health (monitoring app), an app to assess their understanding of their diagnosis and treatment and their readiness to receive treatment (confirmation app), and an app to address mental health issues (writing app); patients assigned to the control group will use only the monitoring app. At baseline (before patients undergo cancer treatment) and three other times during the study, evaluation indicators will be obtained from three different standardized HR-QOL scales that are incorporated in the monitoring app. The study hypothesis is that at 6 months after patients' baseline health monitoring, patients in the experimental group will have improved HR-QOL as compared with patients in the control group. Conclusion: This study is based on self-regulation theory, so it is important that the online support program works in an efficient way with respect to patients finding and setting their own health-related goals and adapting their behaviors to achieve those goals. Verifying the effectiveness of the combination of the three apps will show that it is a scientifically valid approach to maintaining or improving the HR-QOL of cancer patients.

6.
Int Immunopharmacol ; 94: 107394, 2021 May.
Article in English | MEDLINE | ID: mdl-33582590

ABSTRACT

Black soybean hull extract (BSHE) exhibits a variety of biological activities. However, little is known about the effects of BSHE on immunoglobulin E (IgE)-mediated type I allergic reactions. The anti-allergic effect of BSHE was assessed with the degranulation assay using rat basophilic leukemia RBL-2H3 cells and the passive cutaneous anaphylaxis (PCA) reaction in mice. An active compound in BSHE was identified by ultra-performance liquid chromatography coupled to diode array detection and electrospray ionization tandem mass spectrometry analysis. BSHE inhibited the release of ß-hexosaminidase and histamine in RBL-2H3 cells, and cyanidin-3-O-glucoside (C3G) was identified as one of its active compounds. Oral administering of 200 µmol/kg of C3G to IgE-sensitized mice prior to antigen injection suppressed the PCA reaction, as compared with control (p < 0.01). Intravenous administration of BSHE (C3G content, 5.4%) more strongly inhibited PCA responses at lower doses (100 mg/kg, p < 0.01) than oral administration (1,000 mg/kg, p = 0.059). Intravenous C3G also suppressed PCA response at a low dose (40 mg/kg, p < 0.05), showing the same trend as BSHE. This information can be useful to design appropriate formulations of anthocyanin-based drug products to suppress allergic reactions. This study provides evidence for the potential use of BSHE and C3G for the prevention or the treatment of type I allergies.


Subject(s)
Anthocyanins/pharmacology , Anthocyanins/therapeutic use , Cell Degranulation/drug effects , Passive Cutaneous Anaphylaxis/drug effects , Animals , Cell Line , Hexosaminidases/metabolism , Histamine Release/drug effects , Male , Mice, Inbred ICR , Plant Extracts , Rats , Glycine max
7.
J Clin Biochem Nutr ; 67(1): 10-18, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32801463

ABSTRACT

Petasites japonicus (P. japonicus) is a plant of the Asteraceae family. Its roots and stems have been used for the treatment or the prophylaxis of migraine and tension headache as a traditional Chinese medicine in Japan and Korea. Sesquiterpenoids, lignans, and flavonoids are components of P. japonicus. Regarding the biological activity of P. japonicus, its anti-allergic effect has been researched extensively using IgE antigen-stimulated degranulation of RBL-2H3 cells or passive cutaneous anaphylaxis reaction in experimental animal models. The study of the antioxidant activity of P. japonicus was initiated approximately 15 years ago using in vitro assays. In addition, its in vivo effect has also been examined in animal models with induced oxidative injury. Moreover, recently, many types of antioxidant compounds have been rapidly and simultaneously identified using the liquid chromatography-mass spectrometry technique. The number of reports on the other functions of this plant, such as its neuroprotective and anti-inflammatory effects, has been increasing. In this review, I summarized the studies of functional foods derived from P. japonicus, which may provide a basis for the development of potential functional foods. Finally, I discuss the future research avenues in this field.

8.
Biosci Biotechnol Biochem ; 84(3): 621-632, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31762379

ABSTRACT

The antioxidant activity of Petasites japonicus flower buds cultivated in Tokushima, Japan, was examined in vitro and in vivo. The flower bud extracts were assayed using either oxygen radical absorbance capacity or 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity. Antioxidants in the 80% ethanol extract were investigated using online high-performance liquid chromatography-DPPH and were identified as caffeic acid, 3-O-caffeoylquinic acid, fukinolic acid, 3,4-di-O-caffeoylquinic acid, 3,5-di-O-caffeoylquinic acid, and 4,5-di-O-caffeoylquinic acid using liquid chromatography-mass spectrometry. Fukinolic acid was the most active compound based on its activity and abundance. Administering the extracts orally to ICR mice prior to iron injection significantly suppressed plasma thiobarbituric acid reactive substance (TBARS) production. Moreover, TBARS and triglyceride concentrations in the plasma of C57BL/6 mice fed with a high fat diet were also significantly decreased by the extract. The results suggest that antioxidative compounds in P. japonicus can be used in the management of oxidative stress.


Subject(s)
Antioxidants/pharmacology , Flowers/chemistry , Petasites/chemistry , Plant Extracts/pharmacology , Animals , Chromatography, High Pressure Liquid/methods , In Vitro Techniques , Male , Mice, Inbred C57BL , Mice, Inbred ICR , Oxidative Stress/drug effects , Tandem Mass Spectrometry , Thiobarbituric Acid Reactive Substances/metabolism
9.
Pain Med ; 16(5): 1007-12, 2015 May.
Article in English | MEDLINE | ID: mdl-25529255

ABSTRACT

OBJECTIVE: Metastatic bone pain is characteristic of cancer pain and is a form of refractory cancer pain, as the pain includes not only nociceptive but also neuropathic pain. Although some drugs are effective in the management of painful bone metastases, pain while moving is one of the most refractory forms of pain. Although pulsed radiofrequency (RF) dramatically reduces neuropathic pain, chronic pain, and vertebral metastatic pain, the number of cases reported in these studies was very small (five or less). DESIGN: Case report. SETTING: Single pain center. PATIENTS: Fifteen patients suffering from intractable vertebral metastatic pain. INTERVENTIONS: Dorsal root ganglion (DRG) pulsed RF. OUTCOME MEASURES: A numerical rating scale (NRS) of pain at rest and while moving. RESULTS: Almost all patients experienced sound pain relief after the pulsed RF treatment. There were no severe side effects reported. CONCLUSION: DRG pulsed RF procedure provided sound pain relief for patients with intractable vertebral metastatic pain. Metastatic bone pain is characteristic of cancer pain and is a form of refractory cancer pain, as the pain includes not only nociceptive but also neuropathic pain. Although some drugs are effective in the management of painful bone metastases, pain while moving is one of the most refractory forms of pain. DRG pulsed RF procedure provided sound pain relief for patients with intractable vertebral metastatic pain.


Subject(s)
Ganglia, Spinal , Pain Management/methods , Pain, Intractable/therapy , Pulsed Radiofrequency Treatment/methods , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Pain, Intractable/etiology , Retrospective Studies , Spinal Neoplasms/complications , Spinal Neoplasms/secondary
10.
J Nutr Sci Vitaminol (Tokyo) ; 60(2): 129-39, 2014.
Article in English | MEDLINE | ID: mdl-24975223

ABSTRACT

Gly m Bd 28K (Gm28K), a soybean allergen, is formed as a preproprotein consisting of a predicted signal peptide, Gm28K, and the 23-kDa peptide (Gm23K). Gm28K and Gm23K are found in the protein-storage vacuoles (PSVs) of developing soybean seeds. However, the complete structure of Gm28K has not yet been identified and its processing and transport to the vacuoles has never been clarified. In the present study, we elucidated the 5'-nucleotide sequence of cDNA encoding the Gm28K precursor and identified a putative signal peptide (SP) with 24 N-terminal amino acid residues. We expressed peptides from the Gm28K precursor as fusion proteins with enhanced green fluorescent protein (EGFP) in tobacco BY2 suspension-cultured cells. BY2 cells transformed by an expression vector for SP-EGFP-Gm28-Gm23K (SP-EGFP-Gm28-Gm23K/BY2 cells) and SP-Gm28-Gm23K-EGFP/BY2 cells produced the EGFP fused-Gm28K precursor, and the EGFP-fluorescence in their vacuoles were recorded. In the experiments with SP-EGFP/BY2 and SP-EGFP-Gm28K/BY2 cells, large amounts of the EGFP segments were secreted into the medium. On the other hand, the fluorescence of EGFP in SP-EGFP-Gm23K/BY2 cells was shown to accumulate only in the endoplasmic reticulum without secretion into the medium. These findings show that the SP signals the precursor to enter the lumen of the endoplasmic reticulum and that both the Gm28K and Gm23K components may be involved in the transport from the endoplasmic reticulum (ER) lumen via the Golgi to the vacuoles in a proprotein form.


Subject(s)
Allergens/genetics , Antigens, Plant/genetics , Food Hypersensitivity/genetics , Glycine max/genetics , Glycoproteins/genetics , Protein Sorting Signals/genetics , Seeds/metabolism , Soybean Proteins/genetics , Vacuoles/metabolism , Amino Acid Sequence , Antigens, Plant/metabolism , Base Sequence , Biological Transport , Cells, Cultured , Cloning, Molecular , DNA, Complementary , Endoplasmic Reticulum/metabolism , Glycoproteins/metabolism , Green Fluorescent Proteins , Humans , Molecular Sequence Data , Signal Transduction , Soybean Proteins/metabolism , Glycine max/metabolism , Nicotiana/metabolism
11.
J Anesth ; 27(1): 88-92, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22990527

ABSTRACT

PURPOSE: WHO's three step ladder sometimes cannot provide adequate pain relief for pancreatic cancer. Some patients develop terminal delirium (TD). The aim of this study was to test if the addition of a celiac plexus block (CPB) to pharmacotherapy could reduce the incidence of TD. METHODS: Pancreatic cancer patients under the care of our palliative-care team were investigated with regard to the duration and occurrence of TD, pain scores [numerical rating score (NRS)] and daily opioid dose. Between August 2007 to September 2008, 17 patients received only pharmacotherapy (control group). Then, we modified our guideline for analgesia, performing CPB 7 days after the first intervention of our team. Between October 2008 to September 2009, 19 patients received CPB. RESULTS: The opioid doses in CPB group were significantly lower both at 10 days after the first intervention (3 days after CPB) (27 ± 11 vs. 66 ± 82 mg; p = 0.029) and 2 days before death (37 ± 25 vs. 124 ± 117 mg; p = 0.009). NRS in the CPB group were significantly lower both at 10 days after the first intervention (0 [0-2] vs. 3 [2-5], p < 0.0001) and 2 days before death (1 [0-2] vs. 3 [1-4.5], p = 0.018). The occurrence and duration of TD in CPB group were both reduced (42 vs. 94 %, p = 0.019; and 1.8 ± 2.9 vs. 10.4 ± 7.5 days, p = 0.0003). CONCLUSION: The duration and occurrence of TD and the pain severity were significantly less in pancreatic cancer patients who underwent neurolytic CPB.


Subject(s)
Celiac Plexus , Delirium/etiology , Delirium/prevention & control , Nerve Block/methods , Pancreatic Neoplasms/complications , Aged , Delirium/psychology , Female , Humans , Hypotension/etiology , Karnofsky Performance Status , Male , Middle Aged , Nerve Block/adverse effects , Pain Measurement , Pain, Intractable/drug therapy , Pain, Intractable/etiology , Pain, Intractable/therapy , Palliative Care , Pancreatic Neoplasms/psychology , Surgery, Computer-Assisted , Terminal Care , Tomography, X-Ray Computed
12.
Rinsho Ketsueki ; 51(3): 167-73, 2010 Mar.
Article in Japanese | MEDLINE | ID: mdl-20379110

ABSTRACT

The number of hematopoietic stem cell transplantations and recipients with late complications from transplantation are both increasing; therefore, we investigated the status of the long-term follow-up system for hematopoietic stem cell transplantation survivors in Japan using a mail questionnaire; 100 of 194 institutions replied. The median examination time for each patient was 12.5 min. Five percent of institutions had an outpatient transplantation clinic, 1% had a manual for long-term follow-up after stem cell transplantation, and 11% used NIH criteria for the diagnosis of chronic GVHD. The lack of human resources, such as doctors, nurses, and other co-medical staff for transplant patients, was a structural problem. In addition, the development of guidelines for Japanese patients and staff education are also required in the clinical process. Thus, a long-term follow-up system, training of human resources, and appropriate reallocation of funds for medical services are required.


Subject(s)
Hematopoietic Stem Cell Transplantation , Chronic Disease , Follow-Up Studies , Graft vs Host Disease/diagnosis , Graft vs Host Disease/therapy , Health Workforce , Hematopoietic Stem Cell Transplantation/economics , Hematopoietic Stem Cell Transplantation/statistics & numerical data , Humans , Japan/epidemiology , Quality of Life , Reference Standards , Surveys and Questionnaires , Time Factors , Transplantation, Homologous
13.
J Anesth ; 24(3): 407-10, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20217150

ABSTRACT

PURPOSE: Painful neuropathic conditions of cancer pain often show little response to nonopioid and opioid analgesics but may be eased by antidepressants and anticonvulsants. Although gabapentin is effective in the treatment of neuropathic pain in patients with cancer, some patients experience intolerable side effects sufficient to warrant discontinuation. The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine. METHODS: Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally. RESULTS: Low-dose gabapentin-imipramine significantly decreased the total pain score and daily paroxysmal pain episodes. Several patients developed mild adverse symptoms in the four groups, and three patients discontinued treatment due to severe adverse events in the G800 group. CONCLUSION: Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects.


Subject(s)
Amines/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Analgesics, Opioid/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use , Cyclohexanecarboxylic Acids/therapeutic use , Imipramine/therapeutic use , Neoplasms/complications , Pain/drug therapy , Pain/etiology , Peripheral Nervous System Diseases/drug therapy , Peripheral Nervous System Diseases/etiology , gamma-Aminobutyric Acid/therapeutic use , Aged , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antidepressive Agents, Tricyclic/administration & dosage , Drug Therapy, Combination , Female , Gabapentin , Humans , Imipramine/administration & dosage , Male , Middle Aged , Pain Measurement/drug effects
14.
J Cell Physiol ; 216(3): 680-7, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18481257

ABSTRACT

Skin fibrotic disorders such as systemic sclerosis (SSc) are characterized by an excessive accumulation of extracellular matrix (ECM) and are understood to develop under the influence of fibrogenic growth factors. To better understand the detailed mechanisms of persistent fibrosis in SSc, we have previously established an animal model of skin fibrosis induced by exogenous application of growth factors. In this model, transforming growth factor-beta (TGF-beta) transiently induced subcutaneous fibrosis and serial injections of connective tissue growth factor (CTGF) after TGF-beta caused persistent fibrosis. These results suggest that CTGF plays an important role in the development of persistent skin fibrosis and that CTGF may be a potential and specific therapeutic target in skin fibrosis. Therefore, the aim of the current study is to develop a neutralizing monoclonal antibody against human CTGF. We also investigated the neutralizing effect of the antibodies in our animal model. Firstly, by using the DNA immunization method, we developed a panel of anti-CTGF antibodies recognizing the native conformation of human CTGF. Next, to examine the anti-fibrosing effects of these antibodies, newborn B6 mice received subcutaneous injections of TGF-beta for 3 days with either anti-CTGF neutralizing antibodies or control purified immunoglobulin. Anti-CTGF antibodies significantly reduced skin fibrosis and collagen contents compared with the control group. These results suggest that our anti-CTGF antibodies are capable of blocking the development of skin fibrosis at least partially and these anti-CTGF neutralizing antibodies may be useful as the feasible strategy to treat skin fibrotic diseases as SSc.


Subject(s)
Antibodies, Monoclonal/metabolism , Fibrosis/chemically induced , Immediate-Early Proteins/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Transforming Growth Factor beta/pharmacology , Animals , Antibodies, Monoclonal/genetics , Collagen Type I/genetics , Collagen Type I/metabolism , Connective Tissue Growth Factor , Female , Fibrosis/pathology , Humans , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , RNA, Messenger/metabolism , Scleroderma, Systemic/immunology , Scleroderma, Systemic/pathology , Skin/pathology
15.
Rheumatol Int ; 28(2): 113-9, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17628803

ABSTRACT

To determine the prevalence of antibodies to individual histone components in collagen disease patients with anti-U1RNP antibodies. Serum samples were examined by enzyme-linked immunosorbent assay. Patients with mixed connective tissue disease (MCTD) and systemic sclerosis (SSc) showed similar levels and patterns of antihistone antibody (AHA) reactivities to individual histones: IgG responses to H2B or H3 and IgM responses to H2B were highest. However, both IgG and IgM AHAs against outer portion of chromatin (H1, H2A, or H2B) were generally higher in SLE compared with other diseases. SLE or SSc patients with anti-U1RNP antibodies showed generally higher AHA levels than in those without them. Thus, the pattern of reactivities to each histone component was dependent on the disease, while the intensity was dependent on both the disease and anti-U1RNP antibodies. The antigenic stimulus in SLE may be different from other connective tissue diseases and is more likely to be native chromatin.


Subject(s)
Antibody Specificity/immunology , Autoantibodies/blood , Connective Tissue Diseases/immunology , Histones/immunology , snRNP Core Proteins/immunology , Adolescent , Adult , Aged , Autoantibodies/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Middle Aged , Scleroderma, Systemic/immunology , Young Adult
16.
J Rheumatol ; 34(5): 1012-8, 2007 May.
Article in English | MEDLINE | ID: mdl-17309126

ABSTRACT

OBJECTIVE: To investigate the distribution of anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies among patients with autoimmune diseases, and to analyze the clinical features of patients with dermatomyositis (DM) with anti-ARS antibodies. METHODS: Serum samples from 315 patients with autoimmune diseases or related disorders who had visited Kanazawa University Hospital or affiliated facilities were assessed for anti-ARS antibodies by immunoprecipitation. In particular, the association between anti-ARS antibodies and clinical features was investigated in detail in patients with DM. RESULTS: Anti-ARS antibody was positive in 16 (29%) of 55 patients with DM, 2 (22%) of 9 patients with polymyositis, and 7 (25%) of 28 patients with idiopathic pulmonary fibrosis. Although anti-ARS antibody was detected with high frequency (63%, 15/24) in DM patients with interstitital lung disease (ILD), the incidence of anti-ARS antibody was very low (3%, 1/31) in DM patients without ILD. Anti-ARS antibody-positive patients with DM had significantly higher incidences of ILD (94% vs 23%) and fever (64% vs 10%) than the antibody-negative patients. Some immunosuppressive agents, in addition to oral corticosteroids, were required more frequently in the antibody-positive patients with DM than the antibody-negative patients (88% vs 26%). Although 60% of DM patients with ILD simultaneously developed ILD and myositis, ILD preceded myositis in 33% of patients. CONCLUSION: Among patients with DM, anti-ARS antibodies are found in a subset with ILD. DM patients with anti-ARS antibodies appear to have a more persistent disease course that requires additional therapy compared to those without anti-ARS antibodies.


Subject(s)
Amino Acyl-tRNA Synthetases/immunology , Autoantibodies/blood , Dermatomyositis/pathology , Adult , Aged , Aged, 80 and over , Asian People , Autoimmune Diseases/complications , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Dermatomyositis/complications , Dermatomyositis/immunology , Female , Fluorescent Antibody Technique, Indirect , Hospitals, University , Humans , Lung Diseases, Interstitial/complications , Lung Diseases, Interstitial/immunology , Lung Diseases, Interstitial/pathology , Male , Middle Aged , Respiratory Function Tests
17.
Mod Rheumatol ; 16(5): 309-11, 2006.
Article in English | MEDLINE | ID: mdl-17039313

ABSTRACT

We have encountered a 68-year-old Japanese woman with limited cutaneous systemic sclerosis who developed de novo onset of accelerated hypertension and renal dysfunction; thus we diagnosed scleroderma renal crisis. Anticentromere antibody alone was identified, and not anti-DNA topoisomerase I antibody, anti-RNA polymerase antibodies, anti-Th/To antibodies, or antiribonucleoprotein antibodies, even with use of immunoprecipitation assay. She was successfully treated with angiotensin-converting enzyme inhibitor. This case, scleroderma renal crisis with detection of anticentromere antibody, is thought to be extremely uncommon.


Subject(s)
Autoantibodies/blood , Centromere/immunology , Kidney Diseases/etiology , Scleroderma, Limited/complications , Scleroderma, Limited/physiopathology , Aged , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Autoantigens/immunology , Esophagitis, Peptic/complications , Female , Humans , Hypertension/etiology , Liver Cirrhosis, Biliary/complications , Pruritus/complications , Raynaud Disease/complications , Scleroderma, Limited/immunology
18.
J Rheumatol ; 33(8): 1586-92, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16881115

ABSTRACT

OBJECTIVE: To determine the efficacy of self-administered stretching of each finger in Japanese patients with systemic sclerosis (SSc). METHODS: Forty-five patients with SSc (32 with diffuse cutaneous SSc and 13 with limited cutaneous SSc) were given instructions on self-administered stretching and were directed to perform it every day. Individual fingers were maintained in a stretched position using the opposite hand for 10 seconds and this was repeated 3-10 times. To evaluate the effect of the stretching program, finger passive range of motion (ROM) was assessed using a goniometer on the first visit and after 1 month and 1 year of the stretching program. The Health Assessment Questionnaire (HAQ) was also assessed on the first visit and 1 year afterward. RESULTS: The total passive ROM was significantly improved in each finger after 1 month of finger stretching. The total passive ROM was further improved or maintained within 1 year after the first visit. Although ROM was less in patients with diffuse cutaneous SSc than in those with limited cutaneous SSc at the first visit, ROM increased significantly irrespective of disease duration or severity of skin sclerosis. Finger stretching may improve the finger function, since the HAQ score for hand functions such as eating and gripping was significantly decreased. CONCLUSION: Our original self-administered stretching program may be useful for improving finger joint motion in patients with SSc; future studies in various ethnic populations will be needed to determine the universal efficacy of this method.


Subject(s)
Finger Joint/physiopathology , Muscle Stretching Exercises/methods , Scleroderma, Diffuse/therapy , Scleroderma, Limited/therapy , Self Care/methods , Female , Health Status , Humans , Male , Middle Aged , Movement , Range of Motion, Articular , Scleroderma, Diffuse/physiopathology , Scleroderma, Limited/physiopathology , Severity of Illness Index , Surveys and Questionnaires , Treatment Outcome
19.
Am J Hematol ; 81(10): 747-52, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16865687

ABSTRACT

BACKGROUND: Patients who exhibit gastrointestinal (GI) involvement due to graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (SCT) are often recommended to withhold oral intake (NPO) to avoid further damage to the GI mucosa. However, it is possible that continuing oral intake could be beneficial in many patients compared to total parenteral nutrition (TPN). OBJECTIVE: The primary objective of this prospective study was to evaluate whether programmed step-ladder oral dieting (enteral nutrition; EN) is feasible and beneficial for these patients. METHODS: A total of 18 patients who exhibited GI-acute GVHD (stage I to III gut GVHD) after SCT received an EN dieting program, and changes in clinical and laboratory parameters were compared to those in a control cohort of 17 patients who were placed on NPO with TPN. Patients with GVHD were included prospectively and those with intestinal bleeding/obstruction, severe pancreatitis, and cytomegalovirus enterocolitis were excluded. RESULTS: None of the patients in the EN group experienced significant adverse events, including exacerbation of GI symptoms. Although there was no statistically significant difference in the volume or frequency of diarrhea or the time to complete dietary recovery, parameters including body weight and serum levels of total protein and albumin tended to improve faster in the EN group. CONCLUSION: The EN diet is safely applicable to patients suffering from GI involvement by GVHD.


Subject(s)
Enteral Nutrition/methods , Graft vs Host Disease/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Intestinal Diseases/therapy , Adult , Aged , Cohort Studies , Female , Graft vs Host Disease/etiology , Humans , Intestinal Diseases/etiology , Male , Middle Aged , Parenteral Nutrition, Total/methods , Prospective Studies , Time Factors , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...